Roxgold announces first results from development infill drilling on the 55 Zone including 58.1 gpt gold over 4.1 metres
European Regulators Approved Roche's Avastin for Cervical Cancer Treatment
First movers, including Bristol-Myers, and firms that can aggregate a portfolio of immuno-oncology therapies will be positioned well.
These quality funds with smaller asset bases have portfolios built around solid companies.
As incomes rise, emerging-markets consumers can afford more and better medications driving attractive growth in the pharmaceuticals sector, say the managers of Dodge & Cox International Stock.
Large drugmakers are out of favor, but some good funds are banking on a rebound.